Indian domestic formulations: An INR ~5.5 trillion market by 2034

India’s rise as the world’s “pharmacy” has unfolded over distinct phases since the 1970s—beginning with the process patent regime in the 1970–85 period that enabled indigenous manufacturing, followed by export-led scale and quality frameworks in the late 1980s–90s, and a pivot to product R&D and branded formulations in the 1995–2005 run-up to global patent alignment. Post 2005, India emerged as a global generics leader by capitalising on the patent cliff, and since 2015, Indian players have increasingly focused on the fast-growing domestic market, which has more than doubled in value over the last nine years. Within this, chronic therapies have steadily gained share, driven by the rising incidence of lifestyle-related diseases such as diabetes and hypertension.

India’s domestic formulations market has evolved into a largely branded generics (BGx)–driven ecosystem, shaped by historical quality variability that pushed brands and doctors to become proxies for trust. Over the last 15 years, large brands have consistently outpaced industry growth, reinforcing a brand-centric model. At the same time, the pharma supply chain is consolidating, steadily increasing the share and strength of organised players. JB Pharma is a strong example of this trend, having built sustained growth through a powerful brand portfolio, incremental innovation, and value-accretive, therapy-led M&As.

Marketing plays a decisive role in pharma brand building, with companies adopting a two-pronged approach that targets both doctors and patients to drive awareness and reach. To win doctor mindshare, firms deploy large field forces and comprehensive therapy portfolios, often using a “cafeteria” approach to offer holistic treatment solutions, especially across high-density metro and Tier 1 markets where chronic therapies drive superior productivity. This success, however, comes at a significant cost, with field force deployment and doctor engagement forming the largest components of sales and marketing spend. Mankind Pharma’s rise stands out as a counterpoint to the metro-first model, where its sharp micro-market strategy in Tier 2 and smaller towns, enabled it to challenge incumbents, build powerful brands, and grow into a top five pharma company.

As India enters the third stage of its epidemiological transition, lifestyle-led chronic diseases are rising sharply, reshaping the domestic pharma market. Leading pharma companies are firmly pivoting towards chronic specialties such as anti-diabetes, cardiac and neurology, where the growing prevalence of specialty therapies is driving sustained brand-led growth. This shift has created an ideal launchpad for domestic formulation companies, supported by strong sector tailwinds, entrepreneurial talent and expanding access to capital. The success of specialty-focused players such as Eris Lifesciences, along with niche leaders like La Renon and Corona Remedies, underscores how a chronic-first strategy combined with targeted specialist marketing can deliver significant and durable growth.

India’s pharma distribution network remains fragmented, with value-chain leakages inflating drug prices and creating uneven margin structures across branded (BGx) and trade generics (TGx). While BGx follows relatively structured margins, TGx is market-driven, leading companies—especially in Tier 3 and 4 markets—to focus on trade-led push strategies over doctor-led demand. This has resulted in varied TGx go-to-market models, with a few early movers emerging as scaled leaders. Retailers, attracted by higher profitability, are increasingly promoting TGx and GxGx, with organised chains launching private-label generics. However, poor transparency and weak fill rates for lower-priced drugs often push patients toward costlier alternatives. Tech-enabled platforms like TrueMeds are now helping improve access to affordable, quality medicines.

India’s pharma distribution network remains fragmented, with value-chain leakages inflating drug prices and creating uneven margin structures across branded (BGx) and trade generics (TGx). While BGx follows relatively structured margins, TGx is market-driven, leading companies—especially in Tier 3 and 4 markets—to focus on trade-led push strategies over doctor-led demand. This has resulted in varied TGx go-to-market models, with a few early movers emerging as scaled leaders. Retailers, attracted by higher profitability, are increasingly promoting TGx and GxGx, with organised chains launching private-label generics. However, poor transparency and weak fill rates for lower-priced drugs often push patients toward costlier alternatives. Tech-enabled platforms like TrueMeds are now helping improve access to affordable, quality medicines.

The Indian government is strongly focused on building a sustainable, equitable healthcare ecosystem, with India Pharma Vision 2047 centered on improving the affordability, accessibility, and quality of medicines. A series of regulatory reforms is reshaping the pharma value chain, with the most direct impact on manufacturers. The implementation of the revised Schedule M is a significant step toward addressing long-standing quality concerns, and while it may lead to the closure of weaker long-tail units, the top manufacturers are well positioned to absorb the shift. The move to make the Uniform Code for Pharmaceutical Marketing Practices (UCPMP) quasi-statutory further strengthens compliance and ethical standards. Additionally, ongoing initiatives such as INN-based GxGx prescriptions, trade margin rationalisation, and mandatory bio-equivalence studies are expected to progressively enhance access to high-quality, affordable medicines.

While India and Brazil began as broadly similar markets, their regulatory paths diverged sharply, with Brazil’s economic policies and dependence on imported raw materials making it more favourable for MNCs. Early adoption of product patents to attract foreign investment led to a market marked by high prices and low local manufacturing intensity, prompting the Brazilian government to intervene and drive affordability through the introduction of bio-equivalent generics backed by stringent quality, testing, and packaging norms. Globally, successful generics adoption has been shaped by strong regulatory enforcement, government procurement, pricing guidelines, and insurance-led prescribing behaviour. The US, France, and Germany illustrate how robust regulatory frameworks, pharmacist-led substitution, and public healthcare systems have helped build deep and sustainable generics markets.

The Indian pharma market is set to witness a sharp rise in trade generics (TGx) and unbranded generics (GxGx), supported by government procurement and policy push, with volume-driven growth offsetting slower price increases and keeping overall market value stable. As generics deepen, brand-led pharma margins are expected to recalibrate, pushing companies to diversify into OTC, nutraceuticals, diagnostics, and medtech to build new growth engines and engage beyond doctors. At the same time, rising lifestyle diseases and the global shift toward chronic and complex therapies are accelerating R&D, partnerships, and product innovation. With stabilising US healthcare dynamics, an upcoming patent cliff, and faster-growing emerging markets, Indian pharma companies are rebalancing their global strategies. These shifts will reshape business models across pharma, manufacturing, distribution, and retail, while sustained investor interest continues to underscore confidence in the long-term domestic formulations opportunity.